Clinical trials: Pleural Mesothelioma Malignant Advanced
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Unresectable Pleural Mesothelioma
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab +…
- Trial name
- eVOLVE-Meso (NCT06097728)
- Testing
- Volrustomig, Pemetrexed, Carboplatin
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 863 people
- Sponsor
- AstraZeneca
Advanced Malignant Pleural Mesothelioma
Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare disease, but with a very high mortality. MPM is frequently found in advanced stages.
- Trial name
- NCT01869023
- Testing
- Gemcitabine, Cisplatin
- Where
- Mexico
- Volunteers
- 26 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Malignant Pleural Mesothelioma
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced…
- Trial name
- NCT04713761
- Testing
- Toripalimab
- Volunteers
- 15 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Mesothelioma
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used.
- Trial name
- NCT00715611
- Testing
- Pleurectomy/Decortication, pemetrexed and cisplatin or carboplatin, Intensity Modulated Radiation Therapy
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Mesothelioma, Malignant
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
The purpose of this study is to investigate the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy combined with hyperthermia in…
- Trial name
- NCT03393858
- Testing
- Anti-PD-1 antibody, DC-CIK Immunotherapy, Thermotron RF-8EX
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Capital Medical University
Malignant Pleural Effusion, Malignant Pleural Mesothelioma
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor…
- Conditions
- Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural
- Trial name
- NCT05278975
- Testing
- RSO-021
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- RS Oncology LLC
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Malignant Mesothelioma
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether Onconase plus doxorubicin is more effective than doxorubicin alone in…
- Trial name
- NCT00003034
- Testing
- doxorubicin hydrochloride, ranpirnase
- Where
- 19 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Alfacell
Microsatellite High Cancers, Peritoneal Mesothelioma
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
To test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.
- Conditions
- Microsatellite High Cancers, Peritoneal Mesothelioma, Extrapulmonary High Grade, Neuroendocrine Carcinomas
- Trial name
- NCT05337735
- Testing
- XmAb20717
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Mesothelioma, Malignant, Mesothelioma, Malignant Pleural
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma.
- Conditions
- Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
- Trial name
- NCT05188859
- Testing
- Sintilimab+Anlotinib+Pemetrexed+Cisplatin
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Lung cancer is the leading cause of cancer-related death in the United States.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal
- Trial name
- NCT03233724
- Testing
- Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Malignant Mesothelioma
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
RATIONALE: PTK787/ZK 222584 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of PTK787/ZK 222584 in treating patients with unresectable…
- Trial name
- NCT00053885
- Testing
- PTK787/ZK 222584
- Where
- 80 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pleural Mesothelioma Malignant Advanced
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Trial comparing standard treatment (chemotherapy) with pembrolizumab treatment in patients with advanced pretreated malignant mesothelioma.
- Trial name
- PROMISE-meso (NCT02991482)
- Testing
- Pembrolizumab, Gemcitabine, Vinorelbine
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 144 people
- Sponsor
- ETOP IBCSG Partners Foundation
Malignant Mesothelioma
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of raltitrexed in treating patients who have malignant…
- Trial name
- NCT00004254
- Testing
- raltitrexed
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pleural Mesothelioma, Mesothelioma
A Phase 3 Trial in Advanced Epithelioid Mesothelioma
This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior…
- Trial name
- sTEADfast (NCT07824986)
- Testing
- VT3989, gemcitabine, Vinorelbine
- Volunteers
- 350 people
- Sponsor
- Vivace Therapeutics, Inc
Malignant Pleural Mesothelioma
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.
- Trial name
- NCT01486368
- Testing
- PF-03446962
- Where
- 7 sites in Canada
- Volunteers
- 17 people
- Sponsor
- NCIC Clinical Trials Group